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OBJECTIVE—Zinc transporter eight (SLC30A8) is a major
target of autoimmunity in human type 1A diabetes and is
implicated in type 2 diabetes in genome-wide association studies.
The type 2 diabetes nonsynonymous single nucleotide polymor-
phism (SNP) affecting aa325 lies within the region of highest ZnT8
autoantibody (ZnT8A) binding, prompting an investigation of its
relationship to type 1 diabetes.
RESEARCH DESIGN AND METHODS—ZnT8A radioimmuno-
precipitation assays were performed in 421 new-onset type 1
diabetic Caucasians using COOH-terminal constructs incorporat-
ing the known human aa325 variants (Trp, Arg, and Gln). Geno-
types were determined by PCR-based SNP analysis.
RESULTS—Sera from 224 subjects (53%) were reactive to
Arg325 probes, from 185 (44%) to Trp325 probes, and from 142
(34%) to Gln325 probes. Sixty subjects reacted only with Arg325
constructs, 31 with Trp325 only, and 1 with Gln325 only. The
restriction to either Arg325 or Trp325 corresponded with inheri-
tance of the respective C- or T-alleles. A strong gene dosage
effect was also evident because both Arg- and Trp-restricted
ZnT8As were less prevalent in heterozygous than homozygous
individuals. The SLC30A8 SNP allele frequency (75% C and 25%
T) varied little with age of type 1 diabetes onset or the presence
of other autoantibodies.
CONCLUSIONS—The ﬁnding that diabetes autoimmunity can
be deﬁned by a single polymorphic residue has not previously
been documented. It argues against ZnT8 autoimmunity arising
from molecular mimicry and suggests a mechanistic link be-
tween the two major forms of diabetes. It has implications for
antigen-based therapeutic interventions because the response to
ZnT8 administration could be protective or immunogenic de-
pending on an individual’s genotype. Diabetes 57:2693–2697,
2008
H
uman type 1A diabetes results from auto-
immune destruction of pancreatic -cells tar-
geted at a restricted number of autoantigens,
many of which show high -cell speciﬁcity of
expression (1). Susceptibility to the disease is associated
with multiple genetic loci, most prominently HLA alleles
encoding particular major histocompatibility complex
class II glycoproteins (2).
ZnT8 is a newly discovered target of type 1 diabetes
autoimmunity (3) localized to the insulin granule of the
pancreatic -cell. It is encoded by SLC30A8, one of nine
human genes for multispanning transmembrane proteins
facilitating Zn
2 efﬂux from the cell and sequestration into
intracellular compartments (4,5). Recent genome-wide as-
sociation studies demonstrate association of ZnT8 gene
polymorphisms with human type 2 diabetes (6–9), notably
a nonsynonymous SNP encoding either Arg or Trp at aa325.
The major, Arg325-encoding C-allele confers a minor risk
(odds ratio 1.07–1.18) of disease. In nondiabetic subjects
with a family history of type 2 diabetes, the C-allele was
associated with increased insulin sensitivity (10), in-
creased circulating proinsulin-to-insulin ratio (11), and
decreased insulin responses in intravenous glucose toler-
ance tests (12), indicating a dominant effect on insulin
secretion, -cell mass, or both.
We report here that the type 1 diabetes autoimmune
response to ZnT8 is focused on a few key epitopes, two of
which are deﬁned by the polymorphic aa325 residue. To
our knowledge, this is the ﬁrst reported instance where a
polymorphic variant determines the speciﬁcity of the
autoimmune response. It indicates that the autoreactive
B-lymphocyte repertoire is restricted to a few ZnT8
epitopes and is truly self-reactive as opposed to arising as
a bystander response to a foreign antigen.
RESEARCH DESIGN AND METHODS
Serum samples (n  421) were obtained within 2 weeks of type 1 diabetes
diagnosis from patients attending the Barbara Davis Center (median age 11.3
years [range 0.6–58]), 87% Caucasian, and 6.3% Hispanic). The 150 control
subjects (median age 13.1 years [1–55]), 72% Caucasian, and 15.1% Hispanic)
were parents and children in the Diabetes Autoimmunity Study in the Young
(DAISY) general population cohort and parents of the sibling/offspring cohort
(13). The male-to-female sex ratio in both groups was 0.8. Informed consent
was obtained under approved institutional review board oversight.
Genomic DNA was extracted from heparinized blood from 352 of the above
type 1 diabetes patients using standard procedures. Polymorphic variations in
the SLC30A8 gene were determined by qPCR using Taqman probes and an
ABI7000 (ABI, Waltham, MA) targeting the nonsynonymous SNPs rs13266634,
rs2466295 in the 3 untranslated region, and rs6469675 in intron 2. Ascertain-
ment rates were 99%.
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DIABETES, VOL. 57, OCTOBER 2008 2693ZnT8 autoantibody (ZnT8A) radioimmunoprecipitation assays used
35S-
Met–labeled in vitro transcribed and translated probes of hZnT8 COOH-
terminal cytosolic segments (aa268–369) encoding the aa325 codon variants
CCG (Arg), TCG (Trp), and CAG (Gln) (supplementary Fig. 1, available in an
online appendix at http://dx.doi.org/10.2337/db08-0522). Assay procedures
have previously been described (3,14). ZnT8A assay data were normalized to
a panreactive positive control sera (1:50) generated in rabbits to a glutathione-
S-transferase/C-term Trp325 fusion protein and 16 human control sera in the
same assay (3). Recombinant NUS-ZnT8 fusion proteins were generated in
pET43.1 (EMD Biosciences, San Diego, CA), expressed in BL-21(DE3) Esch-
erichia coli, and puriﬁed by Ni-NTA agarose chromatography (Qiagen, Hilden,
Germany). Synthetic 20-mer peptides were from Sigma Genosys (Woodlands,
TX). For preabsorption, sera (5 l) were preincubated with 10 g protein or
peptide in 40 l PBS at 20°C for 2 h before addition of the radiolabeled antigen
to initiate the assay. Results are expressed as means  SD; statistical analyses
were performed with the Prism 4.0 software package (www.graphpad.com).
RESULTS
The present study was initiated to resolve a paradoxical
ﬁnding that two constructs bearing the COOH-terminal
antigenic region of ZnT8 with or without the NH2-terminus
(supplementary Fig. 1) were recognized in a differential
fashion by subsets of type 1 diabetes new-onset sera (3).
The constructs were derived from different cDNAs and
subsequently shown to encode the Arg (C-probe) or Trp
(NC-probe) variants of aa325. To further explore this
phenomenon, assays were performed in sera from newly
diagnosed type 1 diabetic patients using COOH-terminal
ZnT8 probes bearing Arg, Trp, or Gln at aa325: 259 of 421
individuals (61.5%) reacted to at least one probe, with the
highest response recorded in reaction to the Arg variant
(53.2%) followed by Trp (43.9%) and Gln (33.7%) (P 
0.0001, 	
2). Analysis of the overlap in responses (Fig. 1A)
shows that some individuals react to the Arg or Trp probes
alone and very rarely to Gln alone; 29.7% of individuals
reacted to all three probes.
A comparison of the levels of autoantibody reactivity to
the Arg and Gln probes (Fig. 1B) showed that the majority
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FIG. 1. Relationship between autoantibody responses to Arg325, Trp325, and Gln325 constructs. A: Venn diagram illustrating the overlap of antibody
detection with each of the polymorphic probes in the entire population (n  421) in the study. The prevalence in each sector is expressed as a
percentage of the population total. B–D: Assays were performed on the same set of 117 new-onset type 1 diabetic individuals and stratiﬁed as
indicated; the numbers in each sector are shown in parentheses. The cutoff for positive responses was set at 0.05 (vertical and horizontal lines).
Responses judged to be equivalent are set by the boundaries indicated by the angled lines, which correspond to a 3-SD excursion from the
diagonal, assuming an intrassay coefﬁcient of variation of 12.5% for each sample. Data are expressed as the immunoprecipitation index
(sample-control)/(positive sample [BUNE]-control).
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(falling within the bounds of the diagonal of the x-y plot 
3 SD) or responded to the Arg probe alone. Trp and Gln
reactivities (Fig. 1C) were similarly separated. Of the 34
patients who reacted equivalently to Arg and Trp probes
(within the bounds of the diagonal  3 SD of Fig. 1D), 29
(85.3%) had an equivalent response as determined by the
Gln probe. This indicated that for these individuals, the aa
at position 325 was not a determinant of autoantibody
reactivity. A series of preabsorption experiments was
therefore performed using peptides and recombinant pro-
teins as competing ligands (Fig. 2). Selected type 1 diabe-
tes sera that reacted with the Arg probe alone were
blocked by recombinant NUS-C-term Arg325 protein but
not by NUS-C-term Trp325 or NUS-C-term Gln325. Similarly,
Trp-only responses were blocked by NUS-C-term Trp325
but not NUS-C-term Arg325 or NUS-C-term Gln325. Sera that
reacted equivalently to Arg, Trp, and Gln probes were
blocked by any of the NUS-C-term ZnT8 recombinants.
Overlapping 20-mer peptides spanning the ZnT8 COOH-
terminal from 268–369 did not compete for reactivity,
suggesting that the epitopes were conformational rather
than linear. Overall, these results suggest that ZnT8A
reactivity could be accounted for by three classes of
conformational epitopes: one for which Arg325 was an
essential determinant, a second Trp325 restricted, and a
third not affected by aa325.
The relationship between ZnT8 autoantibody reactivity
and genetic variation at the SLC30A8 locus was examined
using the SNP (rs13266634) encoding the Arg/Trp325 vari-
ant and two adjacent noncoding SNPs identiﬁed in a type
2 diabetes genome-wide association study (6), rs2466295,
located 259 bp distally in the 3 UTR, and rs6469675,
located 19635 bp proximally in intron 2. The minor allele
frequency (MAF) for rs13266634 in our type 1 diabetic
population of 0.266 (n  351) approximated the reference
frequency of 0.256 (n  168) for Europeans in the NLM
SNP database (http://www.ncbi.nlm.nih.gov/SNP/snp ref.
cgi?rs  13266634). The distribution of genotypes (55.3%
CC, 36.2% CT, and 8.5% TT) was consistent with Hardy-
Weinberg distribution (53.9, 39.0, and 7.1, respectively).
Similar correlations were observed for the MAF for
rs6469675 (0.285 vs. 0.220 in our study vs. the NLM SNP
database, respectively) and rs2466295 (0.361 vs. 0.407).
The speciﬁcity of the ZnT8A response reﬂected the
rs13266634 genotype (Table 1), with little or no associa-
tion observed with the adjacent rs2466295 and rs6469675
SNPs. The ZnT8A response assessed by the Gln probe
showed no signiﬁcant variation with the rs13266634 geno-
type, whereas responses to the Arg probe were highest in
CC homozygotes, lowest in TT homozygotes, and interme-
diate in the heterozygote group. Conversely, responses to
the Trp probe were highest in TT homozygotes, lowest in
CC, homozygotes, and intermediate in heterozygotes. An
even stronger relationship with genotype was seen in the
groups having only Arg325- and Trp325-restricted responses.
Arg325-only responses were observed only in individuals
bearing the rs13266634 C-allele, with a 4.2-fold higher
frequency in homozygotes than heterozygotes. With one
exception, all Trp325-restricted responses were associated
with the rs13266634 T-allele, with a 10.2-fold higher fre-
quency in homozygotes than heterozygotes. The single
Gln325-restricted ZnT8A patient (Fig. 1A) was genotyped
CC, conﬁrmed by sequencing. The small number of sera
positive for both Trp325 and Arg325 but not Gln325 probes
were associated with heterozygote genotypes (11 of 13
cases) as expected (data not shown). The prevalence of
insulin autoantibody, GAD antibody, or IA-2 antigen
response did not change as a function of rs13266634
genotype.
The median age of onset of disease in the genotyped
individuals was 11.2 years (range 0.6–58), with more than
half (57.3%) diagnosed between ages 8 and 16 years and
88.9% before age 18 years. A frequency distribution analy-
sis based on binning at 4-year intervals showed no statis-
tically signiﬁcant difference in the representation of the
CC, CT, and TT genotypes at any age of onset, though a
trend was observed for a higher CC and lower CT geno-
type frequency in the youngest onset group (0.6–4 years)
compared with that of a 5- to 15-year-old reference group
(Fishers exact test, P  0.24; n  219) (Fig. 3A).
The prevalence of ZnT8A measured with Gln325, Arg325,
and Trp325 COOH-terminal probes increased with increas-
ing age of onset, reached a plateau at 8–16 years, and then
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FIG. 2. Preabsorption of autoantibodies with recombinant proteins.
Single sera samples were selected from hCArg-restricted sera, hCTrp-
restricted sera, or samples that react equivalently with hCGln, hCArg,
and hCTrp probes. Samples were preincubated without (-) or with 10
g of the indicated afﬁnity-puriﬁed NUS-C-term ZnT8 fusion protein
f o r2ha troom temperature before addition of the designated labeled
probe and then processed by the usual procedure.
TABLE 1
Prevalence of autoantibody in relation to rs13266634 genotype
XX
rs13266634 genotype
CC CT TT P
n 351 194 127 30
Any probe 220 (62.7) 128 (66.0) 70 (55.1) 22 (73.3) 0.07
All probes 107 (30.5) 63 (32.5) 37 (29.1) 7 (23.3) 0.55
Gln probe 125 (35.6) 75 (38.7) 42 (33.1) 8 (26.7) 0.33
Arg probe 196 (55.8) 124 (63.9) 63 (49.6) 9 (30.0) 0.0005
Trp probe 154 (43.9) 71 (36.6) 61 (48.0) 22 (73.3) 0.0004
Gln only 1 (0.3) 1 (0.5) 0 (0.0) 0 (0.0) 0.67
Arg only 52 (14.8) 45 (23.2) 7 (5.5) 0 (0.0) 0.0001
Trp only 18 (5.1) 1 (0.5) 5 (3.9) 12 (40.0) 0.0001
Insulin 171 (48.7) 89 (45.9) 68 (53.5) 14 (46.7) 0.39
GAD65 204 (58.1) 108 (55.7) 82 (64.6) 14 (46.7) 0.12
IA-2 254 (72.4) 144 (74.2) 88 (69.3) 22 (73.3) 0.62
Data are n (%) unless otherwise indicated. Serum from each type 1
diabetic subject was assayed with ZnT8 C-term probes incorporating
Gln, Arg, or Trp at aa325 or insulin, GAD65, or IA-2. P values were
calculated by a 3 
 2 Fisher exact test comparing the seropositivitity
(index 0.02) to the number of subjects, stratiﬁed by rs13266634
genotypes. , positive.
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were observed in all age-groups, but the low numbers of
positive individuals did not permit ascertainment of
changes in prevalence and levels of reactivity in associa-
tion with age (Fig. 3D). The autoantibody responses to
insulin, GAD65, and IA-2 showed characteristic changes in
prevalence relative to age of onset of disease, insulin
autoantibody prevalence being highest in younger onset
patients, IA-2 antibody tending to be higher in adolescents
than children, and GAD antibody showing little variation
(Fig. 3B).
DISCUSSION
The COOH-terminal domain of ZnT8 to which type 1
diabetes autoantibodies bind (3) incorporates a conserved
protein fold found in the large family of cation diffusion
facilitator efﬂux carriers and has orthologs in all cellular
organisms (15). Autoantibodies to ZnT8 in human type 1
diabetic patients, however, show little cross-reactivity to
other human Zn transporters or even to mouse ZnT8,
which is 82% identical in sequence. Even more remarkable,
we show here that the amino acid encoded by a common
polymorphism in human ZnT8 at aa325 is a key determinant
of two of the three major conformational epitopes in the
protein. Given that antibody responses in any individual
are polyclonal and the structural variation in the antibody
repertoire that occurs between genetically identical indi-
viduals, such epitope restriction is remarkable and, in light
of this, are termed iso-epitopes. Polymorphic variants of
other diabetes-related autoantigens exist, but to our
knowledge none have been implicated as determinants of
humoral autoreactivity, though clearly this bears further
scrutiny.
The autoantibody responses to the ZnT8 Arg- and Trp-
restricted isoepitopes segregated with the alleles encoding
the respective variant amino acids, indicating that humoral
type 1 diabetes autoimmunity to ZnT8 is directed against
self and not nonself epitope determinants. This argues
against the molecular mimicry hypothesis that suggests
that autoimmunity is triggered by an initial immune re-
sponse to a infectious agent that in turn triggers reactivity
to self because of sequence homology between the patho-
logical agent and a self protein (16–20). Our results favor
the idea that ZnT8 autoreactivity arises because of a defect
in induction of self-tolerance, since the mimicry model
would more likely favor one isoepitope over another,
which in turn would be manifest as genetic dissociation of
the encoding allele with the disease. The MAF of the
rs13266634 SNP in the type 1 diabetic population under
study was, however, similar to reference populations, and
no association of the SNP was seen with age of diabetes
onset or the prevalence of antibodies to ZnT8 or other
diabetes autoantigens. We cannot, however, preclude a
role for molecular mimicry in T-cell recognition of anti-
genic peptides or in antigen presentation to CD4
 T-cells
because antigen/antibody binding can directly inﬂuence
the peptides presented from the antigen by virtue of
altering intracellular proteolytic processing (21,22).
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FIG. 3. Prevalence of genotypes, autoantibodies to ZnT8, and other antigens in relation to age ofclinical diagnosis. Data from 335 individuals were
subdivided in groups 4 years apart and analyzed with respect to distribution of genotypes (A); presence of insulin, GAD, and IA-2 autoantibodies
(B); ZnT8 autoreactivity as deﬁned by Gln, Arg, and Trp probes (C); and ZnT8 autoreactivity relative to isoepitope classiﬁcation (D). Statistical
signiﬁcance relative to the 5- to 15-year-old reference group was determined by Fisher’s exact test: *P < 0.05; **P < 0.01. IAA, insulin
autoantibody.
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speciﬁcites may not markedly affect type 1 diabetes sus-
ceptibility or age of onset, their measurement will be
important in a number of clinical settings. Since ZnT8
autoantibodies provide an independent marker of disease
susceptibility in pre-diabetic individuals (3), measure-
ments based on a single aa325 probe would underestimate
ZnT8 autoimmunity by as much as 20% given the differ-
ences in rs13266634 SNP allele frequency (12) and thus
affect inclusion in clinical trials. Given its high tissue
speciﬁcity, ZnT8 is an attractive candidate as a component
of a DNA- or peptide-based vaccine (23,24) to prevent or
retard the onset of type 1 diabetes. In this context, it is
likely to be important to match the molecular form of the
antigen to the recipient because mismatching the iso-
epitope might lead to immunization and acceleration of
disease rather than induction of tolerance.
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